Heterogeneous expression of A33 in colorectal cancer: Possible explanation for A33 antibody treatment failure

被引：0
|
作者：
Baptistella, A. R. [1 ]
Salles Dias, M. V. [1 ]
Aguiar Junior, S. [2 ]
Begnami, M. D. [3 ]
Martins, V. R. [1 ]
机构：
[1] AC Camargo Canc Ctr, Int Res Ctr CIPE, Sao Paulo, Brazil
[2] AC Camargo Canc Ctr, Pelv Surg, Sao Paulo, Brazil
[3] AC Camargo Canc Ctr, Anat Pathol, Sao Paulo, Brazil
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30143-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [1] Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure
    Baptistella, Antuani R.
    Salles Dias, Marcos Vinicios
    Aguiar, Samuel, Jr.
    Begnami, Maria D.
    Martins, Vilma R.
    ANTI-CANCER DRUGS, 2016, 27 (08) : 734 - 737
  • [2] A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer
    Li, Yan
    Gao, Yuan
    Gong, Chunai
    Wang, Zhuo
    Xia, Qingming
    Gu, Fenfen
    Hu, Chuling
    Zhang, Lijuan
    Guo, Huiling
    Gao, Shen
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018, 14 (07) : 1973 - 1985
  • [3] Phase I study of anticolon cancer humanized antibody A33
    Welt, S
    Ritter, G
    Williams, C
    Cohen, LS
    John, M
    Jungbluth, A
    Richards, EA
    Old, LJ
    Kemeny, NE
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1338 - 1346
  • [4] A33 antigen displays persistent surface expression
    Ackerman, Margaret E.
    Chalouni, Cecile
    Schmidt, Michael M.
    Raman, Vivek V.
    Ritter, Gerd
    Old, Lloyd J.
    Mellman, Ira
    Wittrup, K. Dane
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (07) : 1017 - 1027
  • [5] A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis
    Murer, Patrizia
    Pluess, Louis
    Neri, Dario
    MABS, 2020, 12 (01)
  • [6] A33 antigen displays persistent surface expression
    Margaret E. Ackerman
    Cecile Chalouni
    Michael M. Schmidt
    Vivek V. Raman
    Gerd Ritter
    Lloyd J. Old
    Ira Mellman
    K. Dane Wittrup
    Cancer Immunology, Immunotherapy, 2008, 57 : 1017 - 1027
  • [7] Biodistribution of 211At-Labeled humanized monoclonal antibody A33
    Almqvist, Ylva
    Steffen, Ann-Charlott
    Lundqvist, Hans
    Jensen, Holger
    Tolmachev, Vladimir
    Sundin, Anders
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (04) : 480 - 487
  • [8] Specific Oncolytic Adenovirus Driven by Human A33 Promoter Region for Colorectal Cancer Therapy
    Cafferata, Eduardo G.
    Maccio, Daniela R.
    Lopez, Maria V.
    Viale, Diego L.
    Podhajcer, Osvaldo L.
    MOLECULAR THERAPY, 2006, 13 : S245 - S245
  • [9] Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice
    Barendswaard, EC
    Scott, AM
    Divgi, CR
    Williams, C
    Coplan, K
    Riedel, E
    Yao, TJ
    Gansow, OA
    Finn, RD
    Larson, SM
    Old, LJ
    Welt, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 12 (01) : 45 - 53
  • [10] KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC).
    Bendell, J. C.
    Marshall, J.
    Berlin, J.
    Hochster, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345